Image Analysis Group (IAG), a leader in clinical trial imaging and AI-driven biomarkers, has bolstered its U.S. operations with a new office in Cambridge, Massachusetts. This strategic expansion positions IAG closer to biotechnology and pharmaceutical hubs, enhancing its ability to foster partnerships and offer direct support for regional clinical trials. The Cambridge office is set to assist in the company’s ongoing projects across various therapeutic areas such as oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic diseases, and metabolic diseases.
The new location will enable IAG to collaborate more effectively with sponsors and contract research organizations engaged in Phase I–III clinical trials and imaging-focused development programs. Moreover, IAG is poised to generate employment opportunities locally, with plans to hire in the fields of clinical imaging operations, data science, regulatory support, and business development over the next one to two years. This move underscores IAG’s commitment to providing comprehensive imaging services, including trial design consultation, imaging protocol enhancement, centralized image analysis, and regulatory-compliant data distribution.
As IAG integrates into the Boston life-sciences landscape, the company anticipates improved collaboration with biotechnology firms, pharmaceutical companies, academic institutions, and clinical research centers. This presence is expected to facilitate synergistic partnerships, enhancing the development and execution of clinical trials.
IAG, with its global reach, supports clinical trials across North America, Europe, and the Asia-Pacific region. The company collaborates with pharmaceutical, biotechnology, and medtech companies, as well as CROs, on multi-center studies. Its operations are designed to ensure standardized imaging protocols, centralized data harmonization, and consistent imaging analysis on an international scale.
Founded in 2007 and headquartered in London, IAG operates as an imaging Clinical Research Organization (iCRO). The company is dedicated to supporting pharmaceutical, biotechnology, and medical technology enterprises with imaging-based clinical trial endpoints. Its DYNAMIKA™ platform integrates AI-driven image analysis, centralized quality control, regulatory-compliant reporting, and real-time clinical trial oversight, catering to a diverse range of indications including oncology, inflammatory disease, musculoskeletal, cardiometabolic, and rare diseases.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.